noscript

News and Announcements

Human trials begin in Brisbane, Melbourne for treatment of deadly brain tumours

  • Published November 26, 2014 9:51AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Source: ABC News; Published: Tuesday, 25th November 2014

A world-first human trial set to begin in Brisbane and Melbourne has the potential to be one of the biggest breakthroughs in the treatment of brain cancer, researchers say.

Scientists are confident an antibody created to prolong the lives of people suffering from almost-always fatal Glioblastoma tumour may even offer a cure.

As part of the trial, 20 patients with the recurrent brain tumour will be treated at the Royal Brisbane and Women’s Hospital and the Austin Hospital in Melbourne with the antibody that specifically targets a cancer protein on the surface of the tumour cells.

QIMR Berghofer Medical Research Institute’s professor Andrew Boyd discovered that cancer protein, EphA3, more than 20 years ago.

He also developed the antibody that has been shown to specifically target cancer cells which express EphA3.

To read the full article please click here.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now